Skip to main content
Nashat Gabrail, MD, Oncology, Canton, OH

Nashat Gabrail MD

Breast Cancer, Gynecologic Cancer, Hematologic Oncology


Gabrail Cancer Center

Join to View Full Profile
  • 4875 Higbee Ave NWCanton, OH 44718

  • Phone+1 330-492-3345

  • Fax+1 330-492-0462

Dr. Gabrail is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Founder of Gabrail Cancer Center. Active in clinical research and new anticancer drug development. Special interes in family cancer syndromes and cancer genetics.
    Published the book "Good Medicine is Cheaper Medicine"

Education & Training

  • SSM Health/Saint Louis University School of Medicine
    SSM Health/Saint Louis University School of MedicineFellowship, Hematology and Medical Oncology, 1987 - 1998
  • Hurley Medical Center/Michigan State University
    Hurley Medical Center/Michigan State UniversityResidency, Internal Medicine, 1985 - 1986
  • University of Mosul College of Medicine
    University of Mosul College of MedicineClass of 1976

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 1990 - 2027
  • NC State Medical License
    NC State Medical License 2021 - 2022
  • IA State Medical License
    IA State Medical License 2016 - 2020
  • MI State Medical License
    MI State Medical License 1985 - 1998
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...
    Nashat Y. Gabrail, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phleb...
    Nashat Gabrail, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • Transcenta to Present Two Phase I Clinical Trials of TST001 at Upcoming ASCO GI and IGCC
    Transcenta to Present Two Phase I Clinical Trials of TST001 at Upcoming ASCO GI and IGCCJanuary 12th, 2022
  • Intravenous Iron Replacement Therapy for Iron Deficiency Anemia in Adults
    Intravenous Iron Replacement Therapy for Iron Deficiency Anemia in AdultsJanuary 1st, 2022

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: